Everything You Need to Know About Uplizna Prescribing Information
If you or a loved one has been diagnosed with neuromyelitis optica spectrum disorder (NMOSD), your doctor may prescribe Uplizna. Uplizna is an infusion medication that works by targeting and depleting specific B cells in the immune system, which helps reduce the frequency of NMOSD relapses. However, before starting Uplizna, it is important to understand its prescribing information.
Indications and Usage
Uplizna is indicated for the treatment of adults with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive. It is intended to reduce the frequency of NMOSD exacerbations. Uplizna should be administered by a healthcare provider with experience in the management of NMOSD or similar autoimmune diseases.
Dosing and Administration
The recommended dose of Uplizna is 1200 mg. This should be divided into two infusions, given two weeks apart, with subsequent doses given every six months. The infusion rate should be started at 25 mL/hour and increased by 25 mL/hour every 30 minutes as tolerated, up to a maximum of 200 mL/hour.
Before starting Uplizna, patients should be screened for hepatitis B and tuberculosis. Any infection should be treated before starting Uplizna. Patients should also be monitored for infusion-related reactions and be treated appropriately.
Contraindications
Uplizna is contraindicated in patients who have had a life-threatening infusion reaction to Uplizna or similar medications. It should not be given to patients with an active infection or a history of hepatitis B.
Warnings and Precautions
Patients treated with Uplizna may have an increased risk of serious infections, including progressive multifocal leukoencephalopathy (PML). PML is a rare but serious and potentially life-threatening viral infection of the brain. Other risks associated with Uplizna include infusion-related reactions, liver injury, and decreased neutrophil counts. Patients should be monitored for signs and symptoms of these conditions and be treated appropriately.
Drug Interactions
Uplizna should not be used in combination with other immunosuppressants or biologics.
Conclusion
Uplizna is an important treatment option for adults with anti-AQP4 antibody positive NMOSD. However, it is important to understand its prescribing information, dosing and administration, contraindications, warnings and precautions, and drug interactions. Patients should work closely with their healthcare provider to determine if Uplizna is the right treatment option for them.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)